JWH-212

Synthetic cannabinoid

CaptionSynonyms

JWH-212

Drug Information
Image	200
Identifiers ATC Code DrugBank KEGG ChEBI ChEMBL		Chemical Data Molecular Weight

JWH-212 is a synthetic cannabinoid from the naphthoylindole family, which acts as a potent agonist of the cannabinoid receptors. It was developed by Dr. John W. Huffman and his team at Clemson University as part of research into the structure-activity relationships of cannabinoids.

Pharmacology

JWH-212 is a full agonist at both the CB₁ and CB₂ cannabinoid receptors, with a slight preference for the CB₂ receptor. This receptor selectivity is of interest in research as CB₂ receptors are primarily found in the immune system, and selective CB₂ agonists are being investigated for their potential anti-inflammatory and immunomodulatory effects.

The compound has been shown to have an affinity of 0.69 nM at the CB₁ receptor and 0.60 nM at the CB₂ receptor, indicating high potency. The effects of JWH-212 in vivo have been less extensively studied, but it is expected to produce cannabinoid-like effects such as analgesia, hypothermia, and sedation.

Legal Status

The legal status of JWH-212 varies by country. In the United States, many synthetic cannabinoids, including JWH-212, have been classified as Schedule I controlled substances under the Controlled Substances Act. This classification indicates that they are considered to have a high potential for abuse and no accepted medical use.

In other countries, the legal status may differ, and it is important for researchers to be aware of local regulations when conducting studies involving JWH-212.

Research Applications

JWH-212 is primarily used in scientific research to study the endocannabinoid system and the effects of cannabinoid receptor activation. It serves as a tool for understanding the pharmacological properties of cannabinoids and their potential therapeutic applications.

Research involving JWH-212 and other synthetic cannabinoids has contributed to the development of new drugs targeting the cannabinoid receptors, with potential applications in pain management, neuroprotection, and the treatment of various inflammatory conditions.

Safety and Toxicity

As with many synthetic cannabinoids, the safety profile of JWH-212 is not well established. Synthetic cannabinoids can have unpredictable effects and may pose significant health risks. Adverse effects reported with synthetic cannabinoid use include tachycardia, hypertension, nausea, vomiting, anxiety, and hallucinations.

Also see

• Synthetic cannabinoids
• Cannabinoid receptor
• Endocannabinoid system
• John W. Huffman
• CB1 receptor
• CB2 receptor